On September 21, ASYMCHEM fell 3.55% in regular trading, trading at 151.6 HKD/share, with turnover of approximately 96.72 million HKD, notably diverging from the broader Pharmaceuticals sector which saw broad-based gains on the day.
The decline comes after a period of sharp consecutive rallies, with the stock surging over 8% on September 14 and gaining another 5.71% on September 17, accumulating significant short-term gains. The rapid appreciation has triggered profit-taking pressure from multiple parties. Meanwhile, several major shareholders have recently reduced their positions: JPMorgan sold 289,500 H-shares on September 14 at an average price of 146.80 HKD, lowering its stake to 7.82%; executive Hong Liang sold 59,600 shares on September 15 at an average of 178.23 RMB, reducing his holding to 1.81%; and China Southern Asset Management sold 25,100 shares on September 11 at 132.41 HKD, cutting its stake to 4.93%.
Within the Pharmaceuticals sector, top gainers include Luye Pharma up 6.57%, SBP Group up 5.39%, CSPC Pharma up 4.93%, Hansoh Pharma up 4.20%, and Hengrui Pharma up 2.94%.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments